PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
European Journal of Nuclear Medicine and Molecular Imaging · 2023
DOI: 10.1007/s00259-023-06185-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Nantia Solomonidou und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Freiburg.
Abstract (Originalsprache)
Purpose
The purpose of this retrospective, multicenter study was to assess efficacy of PSMA-PET/CT-guided salvage radiotherapy (sRT) in patients with recurrent or persistent PSA after primary surgery and PSA levels < 0.2 ng/ml.
Methods
The study included patients from a pooled cohort ( n = 1223) of 11 centers from 6 countries. Patients with PSA levels > 0.2 ng/ml prior to sRT or without sRT to the prostatic fossa were excluded. The primary study endpoint was biochemical recurrence-free survival (BRFS) and BR was defined as PSA nadir after sRT + 0.2 ng/ml. Cox regression analysis was performed to assess the impact of clinical parameters on BRFS. Recurrence patterns after sRT were analyzed.
Results
The final cohort consisted of 273 patients; 78/273 (28.6%) and 48/273 (17.6%) patients had local or nodal recurrence on PET/CT. The most frequently applied sRT dose to the prostatic fossa was 66–70 Gy ( n = 143/273, 52.4%). SRT to pelvic lymphatics was delivered in 87/273 (31.9%) patients and androgen deprivation therapy was given to 36/273 (13.2%) patients. After a median follow-up time of 31.1 months (IQR: 20–44), 60/273 (22%) patients had biochemical recurrence. The 2- and 3-year BRFS was 90.1% and 79.2%, respectively. The presence of seminal vesicle invasion in surgery ( p = 0.019) and local recurrences in PET/CT ( p = 0.039) had a significant impact on BR in multivariate analysis. In 16 patients, information on recurrence patterns on PSMA-PET/CT after sRT was available and one had recurrent disease inside the RT field.
Conclusion
This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, German Oncology Center, University Hospital of the European University, Limassol, Cyprus.
- Division of Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
- Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
- Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
- Department of Radiation Sciences (DRS), Institute of Radiation Medicine (IRM), Helmholtz Zentrum, Munich, Germany.
ORCID-Profile: Constantinos Zamboglou
Förderung
- Universitätsklinikum Freiburg
Zitieren
APA
Solomonidou, N., Germanou, D., Strouthos, I., Karagiannis, E., Farolfi, A., Koerber, S. A., Debus, J., Peeken, J. C., Vogel, M. E., Vrachimis, A., Spohn, S. K. B., Shelan, M., Aebersold, D., Grosu, A. L., Ceci, F., Kroeze, S. G. C., Guckenberger, M., Fanti, S., Belka, C., …, & Zamboglou, C. (2023). PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06185-5
Vancouver
Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, et al. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06185-5
BibTeX
@article{Solomonidou2023,
author = {Solomonidou, Nantia and Germanou, Daphnie and Strouthos, Iosif and Karagiannis, Efstratios and Farolfi, Andrea and Koerber, Stefan A and Debus, Juergen and Peeken, Jan C and Vogel, Marco E and Vrachimis, Alexis and Spohn, Simon K B and Shelan, Mohamed and Aebersold, Daniel and Grosu, Anca-Ligia and Ceci, Francesco and Kroeze, Stephanie G C and Guckenberger, Matthias and Fanti, Stefano and Belka, Claus and Hruby, George and Scharl, S and Wiegel, Thomas and Bartenstein, Peter and Henkenberens, Christoph and Emmett, Louise and Schmidt-Hegemann, Nina Sophie and Ferentinos, Konstantinos and Zamboglou, Constantinos},
title = {PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
doi = {10.1007/s00259-023-06185-5}
}
EUVIMED